Drug intelligence / Profile preview

emodin

Development stage
Unknown
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Emodin is a naturally occurring anthraquinone derivative found in the roots and leaves of various plants such as Rheum palmatum (rhubarb) and Polygonum multiflorum. It has been used for centuries in traditional Chinese medicine. Emodin exhibits a wide range of biological activities including anti-inflammatory, antioxidant, anticancer, antimicrobial (antibacterial and antiviral), diuretic, antiulcerative and antinociceptive effects[1][3][4]. Mechanistically, emodin acts as an inhibitor of several cell signaling pathways involved in inflammation and cancer progression. It inhibits nuclear factor kappa-B (NF-κB), JNK/p38 MAPK/Erk1/2 pathways; suppresses pro-inflammatory cytokines such as TNF-α and IL-6; inhibits matrix metalloproteinases like MMP-9; modulates histone deacetylase activity; increases nitric oxide production via eNOS activation; and can inhibit 5-lipoxygenase (5-LOX)[4][5][6]. Emodin also promotes apoptosis in cancer cells by increasing reactive oxygen species (ROS) levels[8]. Despite promising preclinical data for conditions such as cancer, cardiovascular disease (including myocardial hypertrophy/fibrosis), metabolic disorders, liver diseases like hepatitis/cholelithiasis, ulcerative colitis and microbial infections[2][3][4], there are no approved clinical uses or robust human trial data to support its efficacy or safety for any indication[1][5].

Other names
1,3,8-trihydroxy-6-methyl-anthraquinone1,3,8-trihydroxy-6-methylemodin3',4',5',7-tetrahydroxyflavone
02

Targets

MEKPPARG (Peroxisome proliferator-activated receptor gamma)NOS3 (eNOS)ALOX12 (Arachidonate 12-lipoxygenase, 12S type)26S proteasomeHDAC (HDAC family)

Beyond the preview

Go deeper on emodin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on emodin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call